REOPRO SUMMARY
Abciximab, ReoPro®, is the Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation. Abciximab also binds to the vitronectin ((alpha) v(beta)3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.
Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications.
-
in patients undergoing percutaneous coronary intervention
-
in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours
Safety and efficacy ofAbciximab use in patients not undergoing percutaneous coronary intervention have not beenestablished.
Abciximab is intended for use with aspirin and heparin and has been studied only in that setting, as described in CLINICAL STUDIES.
|